3.28
price up icon9.70%   0.29
after-market After Hours: 3.24 -0.04 -1.22%
loading
Vyne Therapeutics Inc stock is traded at $3.28, with a volume of 192.91K. It is up +9.70% in the last 24 hours and up +73.54% over the past month. VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$2.99
Open:
$3.01
24h Volume:
192.91K
Relative Volume:
3.00
Market Cap:
$48.38M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.2971
EPS:
-11.04
Net Cash Flow:
$-26.75M
1W Performance:
+21.93%
1M Performance:
+73.54%
6M Performance:
+25.19%
1Y Performance:
+8.25%
1-Day Range:
Value
$2.96
$3.30
1-Week Range:
Value
$2.57
$3.30
52-Week Range:
Value
$1.57
$4.4808

Vyne Therapeutics Inc Stock (VYNE) Company Profile

Name
Name
Vyne Therapeutics Inc
Name
Phone
800-775-7936
Name
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Name
Employee
10
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
VYNE's Discussions on Twitter

Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-06-21 Resumed H.C. Wainwright Buy

Vyne Therapeutics Inc Stock (VYNE) Latest News

pulisher
Oct 09, 2024

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St

Oct 09, 2024
pulisher
Sep 26, 2024

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance

Sep 26, 2024
pulisher
Sep 24, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

(VYX) Long Term Investment Analysis - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks

Sep 24, 2024
pulisher
Sep 23, 2024

Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha

Sep 23, 2024
pulisher
Sep 23, 2024

Wix.com (NASDAQ:WIX) Upgraded by Piper Sandler to "Overweight" - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World

Sep 23, 2024
pulisher
Sep 20, 2024

Xylem Inc. (NYSE:XYL) Shares Sold by Virtu Financial LLC - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

A company insider recently bought 3,648 shares of NCR Voyix Corp [VYX]. Should You Buy? - Knox Daily

Sep 19, 2024
pulisher
Sep 14, 2024

HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Sep 14, 2024
pulisher
Sep 12, 2024

VYNE reports positive early trial results for inflammation drug - Investing.com

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK

Sep 12, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Sep 12, 2024
pulisher
Sep 03, 2024

VYNE Therapeutics to Participate in September Investor Conferences - StockTitan

Sep 03, 2024
pulisher
Aug 17, 2024

VYNE Therapeutics sees cash runway through end of 2025 - TipRanks

Aug 17, 2024
pulisher
Aug 17, 2024

VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Aug 16, 2024
pulisher
Aug 15, 2024

VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks

Aug 15, 2024
pulisher
Aug 14, 2024

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

Aug 14, 2024
pulisher
Aug 14, 2024

VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace

Aug 14, 2024
pulisher
Aug 08, 2024

Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Aug 08, 2024
pulisher
Jul 24, 2024

VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World

Jul 24, 2024
pulisher
Jul 21, 2024

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way? - Simply Wall St

Jul 21, 2024
pulisher
Jul 16, 2024

VYNE Therapeutics secures UK patent for inflammation drug - Investing.com

Jul 16, 2024
pulisher
Jul 16, 2024

Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC

Jul 16, 2024
pulisher
Jul 16, 2024

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Jul 16, 2024
pulisher
Jul 11, 2024

One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance

Jul 11, 2024
pulisher
Jul 09, 2024

VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz

Jul 09, 2024
pulisher
Jul 09, 2024

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan

Jul 09, 2024
pulisher
Jul 05, 2024

How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia

Jul 05, 2024
pulisher
Jul 04, 2024

VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St

Jul 04, 2024
pulisher
Jul 03, 2024

VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times

Jul 03, 2024
pulisher
Jun 30, 2024

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World

Jun 30, 2024
pulisher
Jun 28, 2024

Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow

Jun 28, 2024
pulisher
Jun 26, 2024

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan

Jun 26, 2024
pulisher
Jun 26, 2024

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewswire Inc.

Jun 26, 2024
pulisher
Jun 18, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo News UK

Jun 18, 2024
pulisher
Jun 16, 2024

Eventide Asset Management LLC Takes $3.25 Million Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 16, 2024
pulisher
Jun 14, 2024

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences - Investing.com India

Jun 14, 2024
pulisher
Jun 14, 2024

H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Canada

Jun 14, 2024
pulisher
Jun 14, 2024

VYNE Therapeutics (NASDAQ:VYNE) Rating Reiterated by HC Wainwright - Defense World

Jun 14, 2024
pulisher
Jun 14, 2024

Analyst Scoreboard: 4 Ratings For VYNE TherapeuticsVYNE Therapeutics (NASDAQ:VYNE) - Benzinga

Jun 14, 2024
pulisher
Jun 13, 2024

Fostering Mentorship and Support in Early-Stage Physician Assistants - Dermatology Times

Jun 13, 2024
pulisher
Jun 13, 2024

VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Jun 13, 2024

Vyne Therapeutics Inc Stock (VYNE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):